SPERO THERAPEUTICS INC. - COMMON STOCK

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

09 8 2022 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application

27 6 2022 15:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update

16 5 2022 15:05:01 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming Investor Conferences

11 5 2022 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022

09 5 2022 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline

03 5 2022 06:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases

21 4 2022 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine

06 4 2022 16:31:32 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update

31 3 2022 15:05:01 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022

17 3 2022 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting

16 2 2022 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

19 1 2022 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720

04 1 2022 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis

03 1 2022 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming Investor Conferences

17 11 2021 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update

10 11 2021 15:05:03 提供 Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

03 11 2021 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis

28 10 2021 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors

12 10 2021 07:05:00 提供 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 10 2021 15:01:00 提供 Nasdaq GlobeNewswire